<DOC>
	<DOCNO>NCT00990249</DOCNO>
	<brief_summary>The goal clinical research study test safety give clofarabine combination busulfan , follow allogeneic ( donor ) stem cell transplant , patient advance leukemia lymphoma .</brief_summary>
	<brief_title>Busulfan Plus Clofarabine Followed Allogeneic Hematopoietic Stem Cell Transplantation</brief_title>
	<detailed_description>Study Treatment : Busulfan design bind DNA ( genetic material cell ) , may cause cancer cell die . It commonly use stem cell transplant . Clofarabine design interfere growth development cancer cell . A stem cell transplant design help body attack cancer cell may remain body chemotherapy . Central Venous Catheter Placement : If find eligible take part study , central venous catheter ( CVC ) place . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form . The study drug stem cell give vein CVC . The CVC remain body 3 month . Study Drug Administration Stem Cell Transplant : You first receive low-level `` test '' dose busulfan vein , either 45 60 minute , Day -8 ( 8 day transplant ) . A heparin lock place vein low number needle stick need blood draw . This involve place intravenous ( IV ) line low arm remain place Day -8 Day -6 . Blood ( 1 teaspoon time ) drawn pharmacokinetic ( PK ) test 11 time 11 hour busulfan dose Day -8 . PK test measure amount study drug body different time point . This PK test do find dose busulfan need body size day receive busulfan . Each day Day -6 Day -3 , receive clofarabine vein 1 hour body-specific dose busulfan vein 3 hour . If reason could PK test perform , receive standard busulfan dose day . The PK testing repeat Day -6 . Blood ( 1 teaspoon time ) drawn PK test 11 time 11 hour busulfan dose . If donor relate his/her tissue HLA-matched ( genetically match ) , receive antithymocyte globulin ( ATG ) vein 4 hour day Day -3 Day -1 . ATG design weaken immune system order low risk body reject transplant . On Day 0 , receive donor 's bone marrow blood stem cell vein . The infusion last anywhere 30 minute several hour . You also receive tacrolimus methotrexate weaken immune system low risk graft-versus-host disease ( GVHD ) . GVHD reaction donor 's immune cell recipient 's body . - Tacrolimus give vein 24 hour every day , start Day -2 continue able take tacrolimus mouth . Once take tacrolimus mouth , take every day 6 month . If develop GVHD , doctor may decide need take tacrolimus longer 6 month . - Methotrexate give vein 15 minute Days 1 , 3 , 6 , 11 transplant . Starting 1 week transplant , receive filgrastim ( G-CSF ) injection skin day blood cell level return normal . Other Possible Treatments : If history leukemia lymphoma brain , receive spinal tap chemotherapy several time 12 month transplant . The chemotherapy drug infuse minute , spinal tap , directly space around spinal cord . Based standard care , doctor decide often occur chemotherapy drug use ( either methotrexate cytarabine ) . If certain type leukemia ( Philadelphia chromosome positive acute lymphoblastic leukemia [ ALL ] ) , receive additional drug help prevent cancer return . The drug imatinib mesylate another similar type drug doctor decide . It give mouth , every day 1 year transplant . Length Study Participation : You hospital 4 week transplant . You take study disease get bad . The study drug stop intolerable side effect occur . Follow-Up : At 1 , 3 , 6 , 12 month transplant , follow test procedure perform : - Blood ( 4 tablespoon ) draw routine test . - You bone marrow aspiration check status disease . To collect bone marrow aspirate , area hip numb anesthetic , small amount bone marrow withdrawn large needle . - If disease bone marrow time diagnosis , CT and/or positron emission compute tomography ( PET ) scan check status disease . The study staff stay contact local doctor find leukemia lymphoma come back , well check . This investigational study . Busulfan clofarabine commercially available FDA approve treatment cancer . Busulfan also FDA approve use stem cell transplant . The use drug together stem cell transplant investigational . Up 150 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<criteria>1 . Patients biopsyproven acute lymphoblastic leukemia , acute lymphoblastic lymphoma , acute biphenotypic leukemia remission relapse . 2 . Adequate renal function , define estimate serum creatinine clearance &gt; 60 ml/min . 3 . Bilirubin equal less 1.5 ( unless Gilbert 's Syndrome ) , serum glutamate pyruvate transaminase ( SGPT ) &lt; 3 X upper limit normal alkaline phosphatase &lt; 2 X upper limit normal . 4 . Adequate pulmonary function force expiratory volume one second ( FEV1 ) , force vital capacity ( FVC ) diffusion capacity lung carbon monoxide ( DLCO ) least 45 % expect corrected hemoglobin . Children unable perform pulmonary function must oxygen saturation great 92 % room air . 5 . Adequate cardiac function leave ventricular ejection fraction least 45 % appropriate medical therapy . No uncontrolled arrhythmias symptomatic cardiac disease . 6 . Zubrod performance status &lt; 2 Lansky/Karnofsky PS equal great 70 % . 7 . Patients must relate , genotypically HLA identical donor , must unrelated donor 8/8 HLA match high resolution type . 8 . Patient patient 's legal representative , parent ( ) guardian provide write informed consent . Assent minor participant 's age least seven less eighteen year . 9 . Negative Beta Human Chorionic Gonadotropin ( HCG ) test woman child bear potential define postmenopausal 12 month previous surgical sterilization . 1 . Patients unresolved grade &gt; 2 nonhematologic toxicity previous therapy . Patients grade 2 toxicity eligible discretion PI . 2 . Patients active central nervous system ( CNS ) disease . 3 . Evidence acute chronic active hepatitis cirrhosis . 4 . Uncontrolled infection , include HIV , HTLV1 , hepatitis B hepatitis C viremia . 5 . Patients great 65 yearsold . 6 . Prior autologous allogeneic hematopoietic stem cell transplant .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>Acute lymphoblastic lymphoma</keyword>
	<keyword>acute biphenotypic leukemia</keyword>
	<keyword>Allogeneic hematopoietic cell transplantation</keyword>
	<keyword>HCT</keyword>
	<keyword>Stem Cell Transplant</keyword>
	<keyword>Treatment-related mortality</keyword>
	<keyword>Tyrosine kinase inhibitor</keyword>
	<keyword>TKI</keyword>
	<keyword>Busulfan</keyword>
	<keyword>Busulfex</keyword>
	<keyword>Myleran</keyword>
	<keyword>Clofarabine</keyword>
	<keyword>Clolar</keyword>
	<keyword>Clofarex</keyword>
	<keyword>Gleevec</keyword>
	<keyword>Imatinib Mesylate</keyword>
</DOC>